EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion. The option begins a due diligence period for EHSI and also begins good faith negotiations between both parties with the intention of reaching a potential Sub-License Agreement. Regenevita (www.regenevita.com) is a subsidiary of Stematix, Inc. (www.stematix.com), and is a joint venture between Stematix and EDCO Ventures (www.edcoonline.org) with a goal to establish pioneering leadership in regenerative medicine for the Rio Grande / Rio Bravo Valley. Regenevita believes it has a unique, sustainable cellular banking model that can facilitate the widespread use of regenerative cell therapy.

“Our participation in this deal has the potential to reap generous rewards for our company in both revenue and technological advancements.”

"We are very impressed with the leadership and development team of Regenevita. It is our belief they have the ability to emerge as world leaders in the advancement of stem cell technology and research," stated Cindy Morrissey, President of EHSI. "Our participation in this deal has the potential to reap generous rewards for our company in both revenue and technological advancements."

Regenevita plans to initially establish two cellular banking operations: one in McAllen, Texas and the other in Reynosa, Mexico. The Reynosa bank will be located in the newest maternity hospital in Reynosa (opened in 2008) under a 50/50 joint venture with the Secretaria de Salud (Ministry of Health) of the Mexican State of Tamaulipas. The Regenevita facilities will initially bank umbilical cord blood from patient donations and for private families, and Regenevita plans to add capabilities and services to support regenerative medicine delivery in future years.

Emerging Healthcare Solutions focuses on the development of profitable emerging medical technology, a sector that also includes Amgen (NASDAQ: AMGN), Dendreon Corporation (NASDAQ: DNDN), Smith & Nephew Plc (NYSE: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).

Source:

Emerging Healthcare Solutions

Comments

  1. Jugs Jugs United States says:

    I am and egg donor and I had stem cells harvested several years ago after a miscarriage - now I have been diagnosed with Parkinson's and your basically telling me that you have taken technology developed and patented in the US and given it away to some foreign government so they can use it however they want. AND WE WONDER why the MEXICANS want to come to the US - why don't we just give them ALL our technology!!!

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL